RxDoctor Payments Data

Elizabeth Adwa

Psychiatric/Mental Health · Wilmington, DENPI 1396224895

Payments from drug & device makers

$1,193in general payments, 2019–2025

Across 16 payments — averaging $74.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Phathom Pharmaceuticals, Inc.$241
  • Sage Therapeutics, LLC$119
  • Inspire Medical Systems, Inc.$113
  • Gilead$107
  • GSK$101
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$100
  • plus $411 from 7 others

What the payments were for

  • Food & beverage$1,193100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,193 in reported general payments places this provider in the 60th percentile of 177 psychiatric/mental health providers in Delaware.

See all psychiatric/mental health providers in Delaware

Medicare billing

Part B allowed, 2024
$6,040
Medicare patients
48
Services billed
85

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Clozapine21$2,644
Aripiprazole22$710
Oxcarbazepine11$617
Quetiapine Fumarate39$475
Ziprasidone Hcl12$448
Fluoxetine Hcl22$319
Clonazepam22$261
Buspirone Hcl29$252
Sertraline Hcl21$217
Olanzapine22$195
Trazodone Hcl17$190
Mirtazapine19$170
Lamotrigine16$143
Lorazepam23$129
Bupropion XlBupropion Hcl11$122

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCOlanzapine$74$19522 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 177 psychiatric/mental health providers in Delaware.

Other psychiatric/mental health in Wilmington

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →